Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: A method and device for the high speed fluid (preferably water) jet removal of dental caries. The water jet is of a controlled upper and lower speed and pressure with a low speed and pressure being of at least 5 to 10 kpsi, sufficient to pierce and flush decayed tissue of a caries with a small beam fluid jet diameter. A pulsed or continuous fluid jet is used to remove and completely flush caries material from a tooth in a time period of under a second with a maximum stagnation pressure of about 30 kpsi, at which point healthy dentin is affected. A coherent or pseudo-coherent water jet operating at high stagnation pressure (range 10,000 to 20,000-psi and no more than 30-kpsi), in a brief burst (.apprxeq.1 second) and small beam diameter (30 to 100-.mu.m) will cleanly remove caries without damage to the tooth structure in particular the sound dentin at the boundary of the caries. No anaesthetic is accordingly required in the absence of a possible exposed nerve.

Abstract: The invention provides benzo[b]indenothiophene compounds, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.

Abstract: Different print quality modes in a printer such as a color inkjet printer invoke different print rendering options for a particular object to be printed. In an exemplary embodiment, a printer control automatically invokes an error diffusion haltoning technique for photo images whenever high quality mode is designated, and automatically invokes a dither haltoning technique for photo images whenever a normal or fast print mode is designated.

Abstract: Different print quality modes in a printer such as a color inkjet printer invoke different print rendering options for a particular object to be printed. In an exemplary embodiment, a printer control automatically invokes an error diffusion haltoning technique for photo images whenever high quality mode is designated, and automatically invokes a dither haltoning technique for photo images whenever a normal or fast print mode is designated.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.

Abstract: The present invention relates to a method and system for efficient image handling. The invention includes an image server with which image files are registered. The image processing requests are sent to the image server to produce image data representing the processed image file. In one embodiment of the invention, a document processing application obtains an image file for printing. The application registers the image with the image server. The image server returns an identifier identifying the image file which is used for subsequent image processing requests. The application initiates a print job, sending the image identifier and selected print parameters to a printer driver. In response, the printer driver negotiates image processing requests with the image server to modify the image file in accordance with the selected print parameters. Finally, the processed image data is retrieved from the image server and sent to the printer.

Abstract: The invention provides benzo?b!indenothiophene compounds of formula I ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6, are as defined in the specification, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: The invention provides dihydrobenzo?b!indenothiophene compounds, intermediates, processes, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: Method and apparatus prepare an image for printing--and in some cases include an output stage, performing the actual printing--when the overall number of pixels is being scaled up or down from an original image or portion. Image-sharpening procedures are controlled automatically by a function of the number of pixels in the original image and the number in the output device. Any of a great variety of such functions may be used, but we prefer a step-function of a ratio of the two pixel counts--particularly a two-valued step-function in which one value is zero and the other serves as a sharpening factor in a sharpening algorithm. When the function yields its zero value, for efficiency the sharpening computations are preferably turned off. The nonzero value is automatically selected when the number of output pixels is more than twice the number of input pixels. The sharpening-factor value, ideally two, is multiplied by the deviation of each image element, e. g.

Abstract: A method of using a printer system for identifying one or more different types of color objects in a document, selecting a preferred rendering option such as halftoning and/or color matching for each one of such different color object types, respectively, and then printing the document in accordance with the rendering options selected for each of such different color object types. In a printing system such as an inkjet color printer coupled through a printer driver to a host computer, a default halftoning technique and a default color-matching map are incorporated into the printer system for automatic invocation whenever a particular color object type is printed.